scholarly journals Psychological treatment of depression and anxiety in patients with co-morbid personality disorder: A scoping study of trial evidence

2017 ◽  
Vol 11 (2) ◽  
pp. 101-117 ◽  
Author(s):  
L.R.M. French ◽  
K.M. Turner ◽  
S. Dawson ◽  
P. Moran
Keyword(s):  
Personality Disorder ◽  
Psychological Treatment ◽  
Depression And Anxiety ◽  
Scoping Study ◽  
Treatment Of Depression ◽  
Trial Evidence

scholarly journals Improving Access to Psychological Therapies (IAPT) - The Need for Radical Reform

2018 ◽  
Vol 23 (9) ◽  
pp. 1136-1147 ◽  
Author(s):  
Michael J Scott
Keyword(s):  
Anxiety Disorders ◽  
Psychological Treatment ◽  
Structured Interview ◽  
Diagnostic Interview ◽  
Personal Injury ◽  
Depression And Anxiety ◽  
Modus Operandi ◽  
Radical Reform ◽  
Psychological Therapies ◽  
Treatment Of Depression

Improving Access to Psychological Therapies is a UK government-funded initiative to widen access to the psychological treatment of depression and anxiety disorders. The author has had the opportunity to independently assess 90 Improving Access to Psychological Therapies clients, using a standardised semi-structured interview, the Structured Clinical Diagnostic Interview for DSM Disorders (SCID) and to listen to their account of interaction with the service. The results suggest that only the tip of the iceberg fully recovers from their disorder (9.2%) whether or not they were treated before or after a personal injury claim. There is a pressing need to re-examine the modus operandi of the service.

scholarly journals Ketamine—New Possibilities in the Treatment of Depression: A Narrative Review

Life ◽  
2021 ◽  
Vol 11 (11) ◽  
pp. 1186
Author(s):  
Mateusz Kowalczyk ◽  
Edward Kowalczyk ◽  
Paweł Kwiatkowski ◽  
Łukasz Łopusiewicz ◽  
Monika Sienkiewicz ◽  
...  
Keyword(s):  
Antidepressant Effect ◽  
Depression Symptoms ◽  
Drug Resistant ◽  
Depression And Anxiety ◽  
Psychoactive Substances ◽  
Worldwide Population ◽  
Treatment Of Depression ◽  
Resistant Depression ◽  
Depressive Episodes ◽  
Rapid Treatment

The SARS-CoV-2 coronavirus epidemic has led to an increase in the number of people with depression. Symptoms related to the mental sphere (mainly depression and anxiety) may be experienced by one third of the worldwide population. This entails the need for the effective and rapid treatment of depressive episodes. An effective drug seems to be s-ketamine, which was accepted in March 2019 by the Food and Drug Administration (FDA) for the treatment of drug-resistant depression. This drug provides a quick antidepressant effect with maximum effectiveness achieved after 24 h. It also appears to reduce the occurrence of suicidal thoughts. However, research into undesirable effects, especially in groups of people susceptible to psychotic episodes or those who use alcohol or psychoactive substances, is necessary.

Sign in / Sign up

Export Citation Format

Share Document